Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy

Erscheinungsjahr 2021
ISBN: 978-0-323-85323-1
Verlag: William Andrew Publishing

Buch, Englisch, 390 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 720 g

Reprogramming the Genome: CRISPR-Cas-based Human Disease Therapy, presents the collation of chapters written by eminent scientists worldwide. CRISPR-Cas9 is a key technology for targeted genome editing and regulation in a number of organisms including mammalian cells. It is a rapid, simple, and cost-effective solution. CRISPR-Cas system has recently gained much scientific and public attention. This volume covers CRISPR-Cas9 based mammalian genome editing, creating disease models, cancer therapy, neurological, heredity, blood disorders, defective gene correction, stem cells therapy, epigenetic modifications, patents, ethics, biosafety and regulatory issues challenges and opportunities. This book is a key source of information on mammalian genome editing available in a single volume. This book will be useful for beginners in mammalian genome editing and also students, researchers, scientists, policymakers, clinicians and stakeholders interested in genome editing in several areas.

Zielgruppe

<p>This book will be valuable sources of information for not only beginner in area of genome engineering area, but also researchers, students, scientists, clinicians, stakeholders, policy makers and practitioners and many more. </p>

Autoren/Hrsg.

Weitere Mitwirkende

Singh, Vijai

Fachgebiete

• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)

Inhaltsverzeichnis

1. An introduction to CRISPR-Cas systems for reprogramming of the genome of mammalian cells 2. CRISPR-Cas systems for genome editing of mammalian cells 3. Genome-wide detection and analysis of CRISPR-Cas off-targets 4. CRISPR-based diagnostics for detection of pathogens 5. Creating cell lines for mimicking diseases 6. Modulating Cas9 activity for precision gene editing 7. Crispr-Cas9 in cancer therapeutics 8. CRISPR-Cas9 for treating heredity diseases 9. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals 10. Recent advances in stem cells & gene editing: Drug discovery and therapeutics 11. Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms 12. Genome editing in cardiovascular diseases 13. CRISPR/Cas9 in epigenetics studies of health and disease 14. Patents, ethics, biosafety and regulation using CRISPR technology

Über Autor(innen)

Singh, Vijai
Prof. Vijai Singh is currently serving as Head of the Department of Biosciences, School of Science and Dean (Research & Innovation) at Indrashil University, Rajpur, Mehsana, India. Prior to this, he held the position of Associate Professor in the same department at Indrashil University. He has also served as Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, and in the Department of Biotechnology at the Invertis University, Bareilly, India. Earlier of his career, Prof. Singh worked as a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and at the School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He earned his Ph.D. in Biotechnology in 2009 from the ICAR-National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India. His doctoral research focused on the development of molecular and immunoassays for the diagnosis of Aeromonas hydrophila. Prof. Singh's research interests lies in the design and construction of novel biosynthetic pathways for production of medically and industrially important biomolecules. His laboratory is also actively engaged in developing CRISPR-Cas systems for gene knock out, knock in, gene regulation and diagnostic. With over 15 years of research and teaching experience, his areas of expertise include synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has an extensive academic record, with over 110 articles, 89 book chapters, 26 books and 3 patents to his credits. Prof. Singh has received number of prestigious awards, including the Bioclues Innovation, Research and Development Award (2023) from the BIOCLUES Society, the Vice Chancellor's Best Research Award (2023) from Indrashil University, and the Agathiyar Chemical Biology Award (2023) from the Society of Chemical and Synthetic Biology. At Indrashil University, he currently serves as chairman of the Board of Study, and is a member of the Academic Council of Indrashil University. He also holds the position of the Member Secretary of the Institutional Biosafety Committee (IBSC) at the university. Dr. Singh is actively involved in national and international scientific advisory roles.